Kornimate/medical-research-clean huggingface dataset:
anti-phobic and safety behaviors in the treatment of acrophobia

Conditions: Specific Phobia

Summary: this study tests whether a single session of exposure therapy may be enhanced by the addition of anti-phobic actions beyond the mere fading of safety behaviors. a total of 100 acrophobic participants will be randomly assigned to receive standard exposure therapy (exp), exposure therapy with safety behavior fading (exp + sbf), exposure with safety behavior fading and anti-phobic actions (exp + sbf + aa), or to a wait-list control group (wl).

this study tests whether a single session of exposure therapy may be enhanced by the addition of one of two augmentation strategies, including engagement in anti-phobic actions and fading of safety behaviors. because utilization of safety behaviors is functionally precluded by anti-phobic action, the present study design will both replicate and extend prior research by addressing whether anti-phobic actions enhance exposure therapy beyond the mere fading of safety behaviors. a total of 100 individuals between the ages of 18 and 65 meeting dsm-iv criteria for acrophobia (fear of heights) will be randomly assigned to one of four conditions including (1) standard exposure therapy, (2) exposure therapy with safety behavior fading, (3) exposure therapy with safety behavior fading and anti-phobic actions, and (4) a wait-list control condition. all participants will complete an online prescreen and face-to-face screening assessment to determine eligibility and pre-treatment symptom severity. participants will also complete assessments at post-treatment and 1-month follow-up assessments. subjective fear during two behavioral approach tests (in the treatment and generalization context, respectively) conducted at pre-treatment, post-treatment, and 1-month follow-up assessments will serve as the primary measure of treatment outcome. additionally, a battery of self-report questionnaires will be completed at pre-treatment, during treatment, at post-treatment, and at a 1-month follow-up assessment.

Eligibility criteria:
inclusion criteria: 1. age 18 to 65. 2. fluent in english (written and spoken). this is required because assessment instruments are validated only in english. 3. meet dsm-iv criteria for specific phobia, natural environment type, with acrophobic concerns, based on the composite international diagnostic interview (cidi-auto; world health organization, 1997). 4. report moderate fear or avoidance (i.e., a score of 30 or higher) on a modified version of the acrophobia questionnaire (aq; cohen, 1977). 5. exhibit at least moderate fear (i.e., a fear score of 50 or higher, where 0 = no fear and 100 = extreme fear) during two behavioral approach tests (bats) consisting of ascending two moderately challenging flights of stairs. exclusion criteria: 1. medical condition(s) which may prevent safely climbing or descending stairs or walking for more than 15 minutes at a time (it will be necessary to walk to different sites for the behavioral approach tests).

Keywords: exposure therapy specific phobia fear of heights acrophobia safety behavior fading anti-phobic actions
pre- mistic: mri and cine imaging to improve staging of tumors in the colon

Conditions: Colon Cancer

Summary: at this moment, we use ct and endoscopy to clinically stage colon tumours. unfortunately, the combination of these imaging techniques is highly inaccurate. 40% of advanced pathological colon tumours (so called t4 tumours) are not staged as a t4 tumour pre-operatively. preoperative or neoadjuvant chemotherapy (nac) has improved outcomes in other gastrointestinal cancers and seems to be a promising pretreatment for colon tumours. to implement nacin colon tumours, we first need to stage the colon tumours with much higher accuracy. mri sequences and cine imaging hold promise to provide more accurate staging of colon tumours.


Eligibility criteria:
inclusion criteria: * patients with clinical suspicion for t3 or t4 tumor based on standard clinical work-up with endoscopy and ct-scan * age \> 18 years * who performance status of 0-2 exclusion criteria: * patients with contraindications for mri * patients with clinical contraindications to undergo colon surgery * patients receiving neoadjuvant therapy prior to surgery * patients with known allergy to iodine or gadolinium contrast * patient with contra-indication for contrasts based on kidney failure neoadjuvant therapy is currently not the standard of care for advanced colon carcinoma, and applied only in selected cases or as part of a clinical trial. because neoadjuvant therapy could result in tumor regression, thus impacting the gold standard of histological examination, patients selected for neoadjuvant therapy are excluded from this study.
lenalidomide plus ice in the treatment of refractory and relapsed dlbcl

Conditions: Diffuse Large B-Cell Lymphoma Refractory

Summary: this study is to evaluate the efficacy and safety of lenalidomide plus ice in the treatment of refractory and relapsed dlbcl patients.


Eligibility criteria:
inclusion criteria: 1. histologically proven diffuse large b-cell lymphoma. previously treated with 1, and only 1, chemotherapy regimen including rituximab and anthracycline. relapse after cr, less than pr or pr to previous treatment. 2. no history of stem cell transplantation. 3. age between 16-75. 4. ecog\<3. 5. at least 1 measurable tumor mass. 6. minimum life expectancy of 3 months. 7. written informed consent. 8. no history of using lenalidomide, ifosfamide, carboplatin and etoposide. 9. no uncontrolled cns involvement by lymphoma:no cns disease at time of relapse;cns disease diagnosed at initial presentation allowed provided a complete response for cns disease was achieved and maintained. exclusion criteria: 1. chemotherapy or large field radiotherapy within 3 weeks prior to entering the study. 2. clinically significant active infection. 3. impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule. 4. any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures. 5. subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment. 6. patients who are pregnant or breast-feeding. 7. hiv infection.
therapeutic efficacy of apd-209 eye drops in treatment of epidemic keratoconjunctivitis (ekc)

Conditions: Viral Conjunctivitis

Summary: a randomized, double-masked, placebo-controlled, multi-centre phase iia proof-of-concept study to evaluate efficacy and safety of apd-209 eye drops for treatment of acute phase adenovirus-induced ekc. the aims of the study are to investigate the therapeutic efficacy of apd-209 eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of ekc (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of apd-209 eye drops in ekc infected eyes.


Eligibility criteria:
inclusion criteria: the patients have to meet all of the following criteria to be eligible to enter the study: * willing and able to provide informed consent. * men or women aged 18 years or above with onset of adenoviral ekc symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent. * using adequate contraceptive measures exclusion criteria: * known or suspected allergy to any ingredient of the imp or placebo. * symptoms correlating with ekc since more than 7 days. * diagnosis of other significant disease(s) than ekc in the eye. * diagnosis of bacterial or fungal ocular infections. * use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. ocular antibiotics may, however, be used until 2 hours prior to first dose of imp, but are thereafter prohibited during the study. * use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion. * use of antiviral medications within 7 days prior to inclusion. * usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes. * usage of any medication or herbal medicinal product for ocular administration at inclusion. * female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period. * known or suspected drug abuse. * usage of contact lenses during the study. * participation in any other interventional clinical study within 30 days prior to inclusion
zenith® spiral-z® aaa iliac leg graft post-market registry

Conditions: Abdominal Aortic Aneurysm; Aorto-iliac Aneurysm

Summary: the purpose of this registry is to obtain case reports of physician experience with the spiral-z® graft under routine clinical care.


Eligibility criteria:
inclusion criteria: * patient is implanted with zenith® spiral-z® aaa iliac leg graft. exclusion criteria: * patients for whom this device would not normally be considered standard of care.

Keywords: abdominal aortic aneurysm iliac leg graft
phase ii study to evaluate the combination of rituximab and depocyte® in the c5r chemotherapy protocol in patients between the ages of 18 and 60 years with primary cerebral non-hodgkin lymphoma and systemic diffuse large b-cell lymphoma with neuromeningeal invasion at diagnosis

Conditions: Lymphoma, Non-Hodgkin; Diffuse Large B-cell Lymphoma

Summary: the purpose of this study is to measure the rate of complete response (cr and ucr) at the end of a course of immuno-chemotherapy: * before cerebral radiotherapy for pcl * after the course of immuno-chemotherapy for aggressive lymphomas with neuromeningeal involvement toxicity of the protocol overall survival survival without relapse long-term incidence of neurocognitive toxicity


Eligibility criteria:
inclusion criteria: * primary cerebral or oculocerebral nhl not previously treated with chemotherapy or radiotherapy and diffuse large b-cell lymphomas, with cerebral and / or neuromeningeal involvement at diagnosis. * diagnosis proved by histological or cytological examination of cerebral specimens, csf or vitreous humour. * diffuse large cell cd20+ lymphoma. * men or women between the ages of 18 and 60 years. * presence of a measurable target to evaluate response. * negative serological tests for hiv, hepatitis b (except in cases of vaccination), hepatitis c. * life-expectancy ≥ 3 months * patient having given written consent to participate in this study. exclusion criteria: * cd20- lymphoma. * history of indolent lymphoma, treated or untreated. * contraindication for one of the products used in polychemotherapy. * known hypersensitivity to mouse antibodies. * absence of measurable target to evaluate response. * history of cancer in the 5 years prior to inclusion except for cutaneous basocellular carcinomas and non-invasive carcinomas of the neck of the uterus. * cardiac contraindication to treatment with anthracyclines or to hyperhydration: severe disturbance of heart rhythm ventricular ejection fraction below 50% history of recent myocardial infarction * previously known severe renal insufficiency and/or creatinaemia \>150 µm/l (apart from invasion of the kidneys by the lymphoma). * total bilirubin \>30 µmol/l, asat, alat \>2.5 times the upper normal value (apart from invasion of the liver by the lymphoma). * insufficient medullary reserve: pnl \< 1 g/l and platelets \<100 g/l (apart from invasion of the medulla by the lymphoma). * history of organ transplantation or other causes of severe immunosuppression. * pregnant woman. * patient incapable of keeping to regular monitoring.

Keywords: lymphoma cerebral lymphoma central nervous system cytarabine rituximab diffuse large b-cell lymphomas, with cerebral or neuromeningeal involvement
safety and efficacy study of ceftaroline in elderly subjects with community-acquired bacterial pneumonia

Conditions: Community-Acquired Bacterial Pneumonia (CABP)

Summary: the purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in elderly subjects with community-acquired bacterial pneumonia (cabp) receiving antibiotic therapy in the hospital.

this is a multicenter study of ceftaroline fosamil in elderly subjects (≥ 65 years of age) with cabp. adjunctive macrolide therapy is to be used at the investigator's discretion. a switch to oral treatment may be allowed at the discretion of the investigator. the total duration of therapy is 5 to 7 days; a minimum of 48 hours of study drug is required.

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 65 years of age. 2. presence of cabp warranting hospitalization. 3. acute illness with ≥ 2 clinical signs or symptoms of lower respiratory tract infection. 4. radiographically confirmed pneumonia. exclusion criteria: 1. history of any hypersensitivity or allergic reaction to any β-lactam or macrolide antibacterial agent. 2. confirmed or suspected respiratory tract infection due solely to an atypical bacterial, mycobacterial, viral, or fungal pathogen. 3. more than 24 hours of potentially effective antibacterial therapy within 96 hours prior to enrollment. 4. life expectancy of \< 30 days or presence of an order of do not resuscitate (dnr). 5. evidence of significant hematologic, hepatic, or immunologic impairment.

Keywords: community-acquired pneumonia lung adult infections
the effect of post-voiding reisdual urine on non-muscle invasive bladder cancer recurrence and progression

Conditions: Bladder Cancer Recurrent; Non-Invasive Bladder Urothelial Carcinoma

Summary: although transurethral resection is the main treatment option for stage ta and t1 disease, relapse is frequently detected. tumor number, tumor size, t stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. the relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. the investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

although transurethral resection is the main treatment option for stage ta and t1 disease, relapse is frequently detected. tumor number, tumor size, t stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. the relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. participants who underwent transurethral resection for bladder tumor will be included in the study. the investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Eligibility criteria:
inclusion criteria: * patients with transitional cell non-muscle invasive bladder cancer (nmibc) pathology * patients with a diagnosis of bladder cancer (nmibc) * patients undergoing transurethral resection for bladder cancer (nmibc) * ≥18 years old patients exclusion criteria: * non-transitional cell bladder cancers * patients with muscle-invasive bladder cancer pathology * \<18 years old patients

Keywords: bladder cancer post voiding residual urine recurrence non-muscle invasive bladder cancer progression
assess safety and efficacy of vilaprisan in subjects with uterine fibroids (asteroid 3)

Conditions: Uterine Fibroids

Summary: the primary objective of this study was to show superiority in the treatment of hmb of vilaprisan in subjects with uterine fibroids compared to placebo. the secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.


Eligibility criteria:
inclusion criteria: * women, 18 years or older in good general health * diagnosis of uterine fibroid(s) documented by ultrasound at screening with at least 1 fibroid with largest diameter ≥ 30 mm and \< 120 mm * heavy menstrual bleeding (hmb) in at least 2 bleeding periods during the screening period each with blood loss volume of \>80.00 ml documented by alkaline hematin (ah) method * an endometrial biopsy performed during the screening period without significant histological disorder such as endometrial hyperplasia (including simple hyperplasia) or other significant endometrial pathology * use of an acceptable non-hormonal method of contraception (ie, either male condom, cap, diaphragm or sponge, each in combination with spermicide) starting at visit 1 until the end of the study exclusion criteria: * pregnancy or lactation (less than 3 month since delivery, abortion, or lactation before start of treatment) * hypersensitivity to any ingredient of the study drug * any condition requiring immediate blood transfusion * laboratory values outside inclusion range before randomization and considered as clinically relevant. * any diseases, conditions, or medications that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug * any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results * abuse of alcohol, drugs, or medicines (eg, laxatives) * use of other treatments that might interfere with the conduct of the study or the interpretation of the results * undiagnosed abnormal genital bleeding

Keywords: heavy menstrual bleeding
evaluating the role of both psma and 64cu-pet/ct total body in patients with locally relapsed prostate cancer

Conditions: Prostate Neoplasms

Summary: the purpose of this study is to assess the detection rate of local relapse after radical prostatectomy with either psma or 64cu-pet/cts and whether the delineation of relapsed lesions using both methods can facilitate/change the therapeutic strategy of the radiation oncologist

pet/tc is a diagnostic tool potentially able to detect, in a single session, both local and distant disease. however, the sensitivity of 18-f-pet/ct in the identification of relapse on the prostatic bed, varies greatly and depends on the value of psa with which the examination is carried out, the size of the relapse in the lodge, the acquisition protocol and it is limited by the physiological hyperaccumulation of the tracer in the bladder. the sensitivity of 18f-choline pet/tc in our hands is significantly higher than the one that is generally reported in the literature (76% with psa values \>1 ng/ml after radical prostatectomy), but still lower than the one of mpmr. pet/ct with 64cu exceeds the limits of 18f-choline pet/tc in the study of the prostatic bed, as the tracer used (64cu) is not excreted by urinary route and therefore does not accumulate in the bladder. this study has the following objectives: primary objective: - to evaluate the detection rate of both 64cu-pet/ct and psma-pet/ct of relapses in patients undergoing radical prostatectomy and subsequent biochemical recurrence; secondary objectives are: * to assess any change in radiation therapy strategy in terms of lesion delineation and dose distribution at planning. * to evaluate the performance of both methods (mpmr and psma/64cu-pet/ct) in assessing the response to radiotherapy with or without androgen deprivation

Eligibility criteria:
criteria: inclusion criteria: * localized prostate adenocarcinoma (m0), any psa value, any gleason score * previous radical surgery with subsequent undetectable psa (\<0.2 ng/ml) * biochemical recurrence (two consecutive psa values of at least 0.2 ng/ml) * m0 to 18f-choline pet/tc * local relapse at mpmr * age\>18 years * performance status 0-1 according to ecog * informed written consent exclusion criteria: * detectable psa after surgery * secondary bone lesions from prostate cancer or m1 * hormone therapy started before staging examinations * previous pelvic radiotherapy * crohn's disease or ulcerative colitis (active phase) * psychiatric diseases * contraindication to mri (metal prostheses, pacemakers, claustrophobia, etc.) * presence of coxo-femoral implants

Keywords: pet-ct scan mpmri prostate neoplasms
protective ventilation during pulmonary lobectomy

Conditions: Pulmonary Complication; Thoracic Surgery; Inflammation

Summary: the investigator will evaluate the influence of lung protective ventilation on postoperative clinical outcome in patients undergoing one-lung ventilation for pulmonary lobectomy.

the hypothesis is that application of low tidal volume, moderate inspired oxygen fraction (fio2) ,intermittent alveolar recruitment and positive end-expiratory pressure (peep) would be more beneficial than conventional ventilation in patients.

Eligibility criteria:
inclusion criteria: 1.20 years and older 2.patients undergoing pulmonary lobectomy exclusion criteria: 1. emergency surgery 2. pulmonary hypertension 3. forced vital capacity or forced expiratory volume in 1 sec \< 50% of the predicted values 4. coagulation disorder 5. pulmonary or extrapulmonary infections 6. history of treatment with steroid in 3 months before surgery 7. history of recurrent pneumothorax 8. history of lung resection surgery
autologous cell therapy for female stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the autologous cell therapy for female sui study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million cook myosite autologous muscle derived cells for treatment of stress urinary incontinence.


Eligibility criteria:
inclusion criteria: * sui with normal detrusor activity confirmed with urodynamics * bladder capacity \>200 ml * incontinence has not shown any improvement for at least -6 months * failed prior treatments (e.g., behavior modification, bladder exercises, biofeedback, electrical stimulation, bulking injections, urethral suspensions and/or drug therapy) exclusion criteria: * known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic floor abnormalities with high pressure instability * neuromuscular disorder (e.g., muscular dystrophy, multiple sclerosis) * uncontrolled diabetes * pregnant, lactating, or plans to become pregnant during course of the study * morbid obesity (defined as 100 pounds over their ideal body weight, or bmi ≥40) and not expected to benefit from treatment * current or acute conditions involving cystitis or urethritis * scheduled to receive radiation treatment to the vicinity, or history of radiation treatment to the urethra or adjacent structures